Gilead Delayed Introduction Of New Version of HIV Drug, With Fewer Side Effects, Maximizing Its Patent Monopoly And Profits
Techdirt has been writing about “evergreening” for many years. It refers to the practice by pharmaceutical companies of making small changes to a drug, often about to come off patent, in order to gain a new patent that extends its manufacturer’s monopoly control over it. The New York Times has a story about the Big...big pharma·drug patents